# A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

> **NCT01297309** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 51 (actual)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** NPSP558

## Key facts

- **NCT ID:** NCT01297309
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-06
- **Primary completion:** 2018-06-08
- **Final completion:** 2018-06-08
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297309, "A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01297309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*